NRCS
NOTICE OF REGISTRATION CONFIRMATION EMAILED
10/07/2025
Back to search
Official data from USPTO
MYELOMA ACTION MONTH
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
MYELOMA ACTION MONTH
ST13
US500000099133159Class
35
Filing
99133159
Registration
7978497
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
13
Latest update
10/08/2025
Classification
Registered
Trademark type
Word
Nice classes
35
Filing date
04/11/2025
Registration date
10/07/2025
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/07/2025
Last transaction
10/08/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Supplemental Register
First use anywhere
02/01/2025
First use in commerce
02/01/2025
Drawing code
4
Owner type
03
Owner location
Studio City, CA
Examiner
REID,MONICA R
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
I. F. (pessoa física)
Representatives
Natasha Shabani Greenberg Glusker Fields Claman & Machtinger LLP
Technical classification
Nice Classes
Class 35
Vienna Codes
No Vienna codes available.
Goods and services
Class 35
Association servicespromoting the public interest and awareness in cancer research and education; Association servicespromoting public awareness of myeloma researchdiagnosis and treatmentthe need for access to a broad range of approved and medically-accepted anticancer regimens; Promoting public awareness of the need for access to a broad range of approved and medically-accepted anticancer regimens; Promoting collaboration within the scientificresearch and provider communities to achieve advances in the field of of myeloma researchdiagnosis and treatment; Promoting public awareness of the need for access to a broad range of approved and medically-accepted anticancer regimen by means of public advocacy
Publications
History of USPTO decisions and trademark events.
13 publications found
R.SR
REGISTERED-SUPPLEMENTAL REGISTER
10/07/2025
CNTA
APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
09/10/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/09/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/09/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/09/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/08/2025
GNRT
NON-FINAL ACTION E-MAILED
09/08/2025
CNRT
NON-FINAL ACTION WRITTEN
09/08/2025
DOCK
ASSIGNED TO EXAMINER
09/08/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/11/2025
MAFR
APPLICATION FILING RECEIPT MAILED
04/11/2025
NWAP
NEW APPLICATION ENTERED
04/11/2025
Continuous trademark protection
Get notified about every new filing that threatens MYELOMA ACTION MONTH or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.